Abstract
Rationale
Zolpidem is a short-acting, non-benzodiazepine hypnotic that acts as a full agonist at α1-containing GABAA receptors. Overall, zolpidem purportedly has fewer instances of abuse and dependence than traditionally used benzodiazepines. However, several studies have shown that zolpidem may be more similar to benzodiazepines in terms of behavioral tolerance and withdrawal symptoms.
Objectives
In the current study, we examined whether subchronic zolpidem or diazepam administration produced deficits in zolpidem’s locomotor-impairing effects, anxiety-like behaviors, and changes in GABAAR subunit messenger RNA (mRNA).
Methods
Mice were given subchronic injections of either zolpidem (10 mg/kg), diazepam (20 mg/kg), or vehicle twice daily for 7 days. On day 8, mice were given a challenge dose of zolpidem (2 mg/kg) or vehicle before open field testing. Another set of mice underwent the same injection regimen but were sacrificed on day 8 for qRT-PCR analysis.
Results
We found that subchronic zolpidem and diazepam administration produced deficits in the acute locomotor-impairing effects of zolpidem and increased anxiety-like behaviors 1 day after drug termination. In addition, we found that subchronic treatment of zolpidem and diazepam induced distinct but overlapping GABAAR subunit mRNA changes in the cortex but few changes in the hippocampus, amygdala, or prefrontal cortex. Levels of mRNA measured in separate mice after a single injection of either zolpidem or diazepam revealed no mRNA changes.
Conclusions
In mice, subchronic treatment of zolpidem and diazepam can produce deficits in the locomotor-impairing effects of zolpidem, anxiety-like withdrawal symptoms, and subunit-specific mRNA changes.
Similar content being viewed by others
References
Acikmese B, Haznedar S, Hatipoglu I, Enginar N (2012) Evaluation of anxiolytic effect and withdrawal anxiety in chronic intermittent diazepam treatment in rats. Behav Pharmacol 23:215–219
Aitta-aho T, Vekovischeva OY, Neuvonen PJ, Korpi ER (2009) Reduced benzodiazepine tolerance, but increased flumazenil-precipitated withdrawal in AMPA-receptor GluR-A subunit-deficient mice. Pharmacol Biochem Behav 92:283–290
Ali NJ, Olsen RW (2001) Chronic benzodiazepine treatment of cells expressing recombinant GABAA receptors uncouples allosteric binding: studies on possible mechanisms. J Neurochem 79:1100–1108
Allison C, Pratt JA (2003) Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacol Ther 98:171–195
Allison C, Claase LA, Pratt JA (2002) Diazepam withdrawal-induced anxiety and place aversion in the rat: differential effects of two chronic diazepam treatment regimes. Behav Pharmacol 13:417–425
Allison C, Pratt JA, Ripley TL, Stephens DN (2005) Alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor autoradiography in mouse brain after single and repeated withdrawal from diazepam. Eur J Neurosci 21:1045–1056
Aragona M (2000) Abuse, dependence, and epileptic seizures after zolpidem withdrawal: review and case report. Clin Neuropharmacol 23:281–283
Araujo F, Tan S, Ruano D, Schoemaker H, Benavides J, Vitorica J (1996) Molecular and pharmacological characterization of native cortical γ-aminobutyric acidA receptors containing both α1 and α3 subunits. J Biol Chem 271:27902–27911
Arnot MI, Davies M, Martin IL, Bateson AN (2001) GABA(A) receptor gene expression in rat cortex: differential effects of two chronic diazepam treatment regimes. J Neurosci Res 64:617–625
Asan E, Yilmazer-Hanke DM, Eliava M, Hantsch M, Lesch K-P, Schmitt A (2005) The corticotropin-releasing factor (CRF)-system and monoaminergic afferents in the central amygdala: investigations in different mouse strains and comparison with the rat. Neuroscience 131:953–967
Atack JR, Hutson PH, Collinson N, Marshall G, Bentley G, Moyes C, Cook SM, Collins I, Wafford K, McKernan RM, Dawson GR (2005) Anxiogenic properties of an inverse agonist selective for α3 subunit-containing GABAA receptors. Br J Pharmacol 144:357–366
Auta J, Giusti P, Guidotti A, Costa E (1994) Imidazenil, a partial positive allosteric modulator of GABAA receptors, exhibits low tolerance and dependence liabilities in the rat. J Pharmacol Exp Ther 270:1262–1269
Auta J, Impagnatiello F, Kadriu B, Guidotti A, Costa E (2008) Imidazenil: a low efficacy agonist at alpha1- but high efficacy at α5-GABAA receptors fail to show anticonvulsant cross tolerance to diazepam or zolpidem. Neuropharmacology 55:148–153
Barnard EA, Skolnick P, Olsen RW, Mohler H, Sieghart W, Biggio G, Braestrup C, Bateson AN, Langer SZ (1998) International union of pharmacology. XV. Subtypes of γ-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 50:291–314
Bateson AN (2002) Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr Pharm Des 8:5–21
Benavides J, Peny B, Dubois A, Perrault G, Morel E, Zivkovic B, Scatton B (1988) In vivo interaction of zolpidem with central benzodiazepine (BZD) binding sites (as labeled by [3H]Ro 15-1788) in the mouse brain. Preferential affinity of zolpidem for the omega 1 (BZD1) subtype. J Pharmacol Exp Ther 245:1033–1041
Benavides J, Peny B, Ruano D, Vitorica J, Scatton B (1993) Comparative autoradiographic distribution of central ω (benzodiazepine) modulatory site subtypes with high, intermediate and low affinity for zolpidem and alpidem. Brain Res 604:240–250
Benca RM (2005) Diagnosis and treatment of chronic insomnia: a review. Psychiatr Serv 56:332–343
Biggio G, Dazzi L, Biggio F, Mancuso L, Talani G, Busonero F, Mostallino MC, Sanna E, Follesa P (2003) Molecular mechanisms of tolerance to and withdrawal of GABAA receptor modulators. Eur Neuropsychopharmacol 13:411–423
Blanchard DC, Griebel G, Blanchard RJ (2001) Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic. Neurosci Biobehav Rev 25:205–218
Burt DR, Kamatchi GL (1991) GABAA receptor subtypes: from pharmacology to molecular biology. FASEB J 5:2916–2923
Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF (1997) Special Report: the 1996 guide for the care and use of laboratory animals. The National Academies Press, Bethesda, MD
Cohen C, Sanger DJ (1994) Tolerance, cross-tolerance and dependence measured by operant responding in rats treated with triazolam via osmotic pumps. Psychopharmacology (Berl) 115:86–94
Crestani F, Löw K, Keist R, Mandelli M-J, Möhler H, Rudolph U (2001) Molecular targets for the myorelaxant action of diazepam. Mol Pharmacol 59:442–445
Cubala WJ, Landowski J (2007) Seizure following sudden zolpidem withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 31:539–540
Davis M (2000) The role of the amygdala in conditioned and unconditioned fear and anxiety. In: Aggleton JP (ed) The amygdala : A functional analysis. Oxford University Press, New York, pp 213–287
Diaz-Garcia JM, Oliver-Botana J, Fos-Galve D (1992) Pharmacokinetics of diazepam in the rat: influence of a carbon tetrachloride-induced hepatic injury. J Pharm Sci 81:768–772
Divljaković J, Milić M, Namjoshi OA, Tiruveedhula VV, Timić T, Cook JM, Savić MM (2013) βCCT, an antagonist selective for α1GABAA receptors, reverses diazepam withdrawal-induced anxiety in rats. Brain Res Bull 91:1–7
Drover DR (2004) Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 43:227–238
Duncan GE, Breese GR, Criswell HE, McCown TJ, Herbert JS, Devaud LL, Morrow AL (1995) Distribution of [3H]zolpidem binding sites in relation to messenger RNA encoding the alpha 1, beta 2 and gamma 2 subunits of GABAA receptors in rat brain. Neuroscience 64:1113–1128
Duncan GE, Knapp DJ, Breese GR, Crews FT, Little KY (1998) Species differences in regional patterns of 3H-8-OH-DPAT and 3H-zolpidem binding in the rat and human brain. Pharmacol Biochem Behav 60:439–448
Ebert B, Anderson NJ, Cremers TI, Rasmussen S, Vogel V, Fahey JM, Sánchez C (2008) Gaboxadol—a different hypnotic profile with no tolerance to sleep EEG and sedative effects after repeated daily dosing. Pharmacol Biochem Behav 90:113–122
Elliot EE, White JM (2000) Precipitated and spontaneous withdrawal following administration of lorazepam but not zolpidem. Pharmacol Biochem Behav 66:361–369
Fahey JM, Pritchard GA, Grassi JM, Pratt JS, Shader RI, Greenblatt DJ (1999) In situ hybridization histochemistry as a method to assess GABA(A) receptor subunit mRNA expression following chronic alprazolam administration. J Psychopharmacol 13:211–218
Fernandes C, File SE, Berry D (1996) Evidence against oppositional and pharmacokinetic mechanisms of tolerance to diazepam's sedative effects. Brain Res Bull 734:236–242
Fernandes C, Arnot MI, Irvine EE, Bateson AN, Martin IL, File SE (1999) The effect of treatment regimen on the development of tolerance to the sedative and anxiolytic effects of diazepam. Psychopharmacology (Berl) 145:251–259
File SE (1985) Tolerance to the behavioral actions of benzodiazepines. Neurosci Biobehav Rev 9:113–121
File SE (1990) The history of benzodiazepine dependence: a review of animal studies. Neurosci Biobehav Rev 14:135–146
Follesa P, Cagetti E, Mancuso L, Biggio F, Manca A, Maciocco E, Massa F, Desole MS, Carta M, Busonero F, Sanna E, Biggio G (2001) Increase in expression of the GABA(A) receptor alpha(4) subunit gene induced by withdrawal of, but not by long-term treatment with, benzodiazepine full or partial agonists. Brain Res Mol Brain Res 92:138–148
Friedman H, Abernethy DR, Greenblatt DJ, Shader RI (1986) The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma. Psychopharmacology (Berl) 88:267–270
Galpern WR, Lumpkin M, Greenblatt DJ, Shader RI, Miller LG (1991) Chronic benzodiazepine administration. VII. Behavioral tolerance and withdrawal and receptor alterations associated with clonazepam administration. Psychopharmacology (Berl) 104:225–230
Garrigou-Gadenne D, Burke JT, Durand A, Depoortere H, Thenot JP, Morselli PL (1989) Pharmacokinetics, brain distribution and pharmaco-electrocorticographic profile of zolpidem, a new hypnotic, in the rat. J Pharmacol Exp Ther 248:1283–1288
Gericke CA, Ludolph AC (1994) Chronic abuse of zolpidem. JAMA 272:1721–1722
Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C (2001) An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 25:386–401
Glisovic T, Bachorik JL, Yong J, Dreyfuss G (2008) RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett 582:1977–1986
Gravielle MC, Faris R, Russek SJ, Farb DH (2005) GABA induces activity dependent delayed-onset uncoupling of GABA/benzodiazepine site interactions in neocortical neurons. J Biol Chem 280:20954–20960
Greenblatt DJ, Roth T (2012) Zolpidem for insomnia. Expert Opin Pharmacother 13:879–893
Griebel G, Perrault G, Letang V, Granger P, Avenet P, Schoemaker H, Sanger DJ (1999) New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (omega) receptor subtypes. Psychopharmacology (Berl) 146:205–213
Griffiths RR, Weerts EM (1997) Benzodiazepine self-administration in humans and laboratory animals—implications for problems of long-term use and abuse. Psychopharmacology (Berl) 134:1–37
Griffiths RR, Sannerud CA, Ator NA, Brady JV (1992) Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal. J Pharmacol Exp Ther 260:1199–1208
Hajak G, Muller WE, Wittchen HU, Pittrow D, Kirch W (2003) Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98:1371–1378
Heikkinen AE, Moykkynen TP, Korpi ER (2009) Long-lasting modulation of glutamatergic transmission in VTA dopamine neurons after a single dose of benzodiazepine agonists. Neuropsychopharmacology 34:290–298
Heldt SA, Ressler KJ (2007) Forebrain and midbrain distribution of major benzodiazepine-sensitive GABAA receptor subunits in the adult C57 mouse as assessed with in situ hybridization. Neuroscience 150:370–385
Heninger C, Saito N, Tallman JF, Garrett KM, Vitek MP, Duman RS, Gallager DW (1990) Effects of continuous diazepam administration on GABAA subunit mRNA in rat brain. J Mol Neurosci 2:101–107
Hoffman JM, Shah ND, Vermeulen LC, Schumock GT, Grim P, Hunkler RJ, Hontz KM (2007) Projecting future drug expenditures–2007. Am J Health Syst Pharm 64:298–314
Holt RA, Bateson AN, Martin IL (1996) Chronic treatment with diazepam or abecarnil differently affects the expression of GABAA receptor subunit mRNAs in the rat cortex. Neuropharmacology 35:1457–1463
Holt RA, Bateson AN, Martin IL (1997) Chronic zolpidem treatment alters GABA(A) receptor mRNA levels in the rat cortex. Eur J Pharmacol 329:129–132
Huang MC, Lin HY, Chen CH (2007) Dependence on zolpidem. Psychiatry Clin Neurosci 61:207–208
Huopaniemi L, Keist R, Randolph A, Certa U, Rudolph U (2004) Diazepam-induced adaptive plasticity revealed by α1 GABAA receptor-specific expression profiling. J Neurochem 88:1059–1067
Impagnatiello F, Pesold C, Longone P, Caruncho H, Fritschy JM, Costa E, Guidotti A (1996) Modifications of gamma-aminobutyric acidA receptor subunit expression in rat neocortex during tolerance to diazepam. Mol Pharmacol 49:822–831
IMS-Health (2011) National (VONA) and total patient tracker (TPT). MS Health, Fairfield, CT
Jacob TC, Michels G, Silayeva L, Haydon J, Succol F, Moss SJ (2012) Benzodiazepine treatment induces subtype-specific changes in GABAA receptor trafficking and decreases synaptic inhibition. Proc Natl Acad Sci USA 109:18595–18600
Jardim MC, Nogueira RL, Graeff FG, Nunes-de-Souza RL (1999) Evaluation of the elevated T-maze as an animal model of anxiety in the mouse. Brain Res Bull 48:407–411
Kang I, Miller LG (1991) Decreased GABAA receptor subunit mRNA concentrations following chronic lorazepam administration. Br J Pharmacol 103:1285–1287
King DA, Bouton ME, Musty RE (1987) Associative control of tolerance to the sedative effects of a short-acting benzodiazepine. Behav Neurosci 101:104–114
Kittler JT, Delmas P, Jovanovic JN, Brown DA, Smart TG, Moss SJ (2000) Constitutive endocytosis of GABAA receptors by an association with the adaptin AP2 complex modulates inhibitory synaptic currents in hippocampal neurons. J Neurosci 20:7972–7977
Korpi ER, Mihalek RM, Sinkkonen ST, Hauer B, Hevers W, Homanics GE, Sieghart W, Luddens H (2002) Altered receptor subtypes in the forebrain of GABA(A) receptor delta subunit-deficient mice: recruitment of gamma 2 subunits. Neuroscience 109:733–743
Kripke DF (2007) Greater incidence of depression with hypnotic use than with placebo. BMC Psychiatry 7:42
Lader M (2011) Benzodiazepines revisited—will we ever learn? Addiction 106:2086–2109
Lau CE, Sun L, Wang Q, Falk JL (2002) The effect of zolpidem on operant behavior and its relation to pharmacokinetics after intravenous and subcutaneous administration: concentration-effect relations. Behav Pharmacol 13:93–103
Liappas IA, Malitas PN, Dimopoulos NP, Gitsa OE, Liappas AI, Nikolaou CK, Christodoulou GN (2003) Zolpidem dependence case series: possible neurobiological mechanisms and clinical management. J Psychopharmacol 17:131–135
Longone P, Impagnatiello F, Guidotti A, Costa E (1996) Reversible modification of GABAA receptor subunit mRNA expression during tolerance to diazepam-induced cognition dysfunction. Neuropharmacology 35:1465–1473
Loscher W, Schwark WS (1985) Development of tolerance to the anticonvulsant effect of diazepam in amygdala-kindled rats. Exp Neurol 90:373–384
Low K, Crestani F, Keist R, Benke D, Brunig I, Benson JA, Fritschy JM, Rulicke T, Bluethmann H, Mohler H, Rudolph U (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290:131–134
Lukas SE, Griffiths RR (1984) Precipitated diazepam withdrawal in baboons: effects of dose and duration of diazepam exposure. Eur J Pharmacol 100:163–171
Marin RH, Pérez MF, Duero DG, Ramirez OA (1999) Preexposure to drug administration context blocks the development of tolerance to sedative effects of diazepam. Pharmacol Biochem Behav 64:473–477
Markowitz GJ, Kadam SD, Boothe DM, Irving ND, Comi AM (2010) The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. Neuroreport 21:452–456
McKernan RM, Whiting PJ (1996) Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci 19:139–143
Mehta AK, Ticku MK (1999) Prevalence of the GABAA receptor assemblies containing alpha1-subunit in the rat cerebellum and cerebral cortex as determined by immunoprecipitation: lack of modulation by chronic ethanol administration. Brain Res Mol Brain Res 67:194–199
Metten P, Belknap JK, Crabbe JC (1998) Drug withdrawal convulsions and susceptibility to convulsants after short-term selective breeding for acute ethanol withdrawal. Behav Brain Res 95:113–122
Miller LG, Woolverton S, Greenblatt DJ, Lopez F, Roy RB, Shader RI (1989) Chronic benzodiazepine administration. IV. Rapid development of tolerance and receptor downregulation associated with alprazolam administration. Biochem Pharmacol 38:3773–3777
Murphy HM, Ihekoronze C, Wideman CH (2011) Zolpidem-induced changes in activity, metabolism, and anxiety in rats. Pharmacol Biochem Behav 98:81–86
Perrault G, Morel E, Sanger DJ, Zivkovic B (1990) Differences in pharmacological profiles of a new generation of benzodiazepine and non-benzodiazepine hypnotics. Eur J Pharmacol 187:487–494
Perrault G, Morel E, Sanger DJ, Zivkovic B (1992) Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem. J Pharmacol Exp Ther 263:298–303
Pesold C, Caruncho HJ, Impagnatiello F, Berg MJ, Fritschy JM, Guidotti A, Costa E (1997) Tolerance to diazepam and changes in GABAA receptor subunit expression in rat neocortical areas. Neuroscience 79:477–487
Petroski RE, Pomeroy JE, Das R, Bowman H, Yang W, Chen AP, Foster AC (2006) Indiplon is a high-affinity positive allosteric modulator with selectivity for α1 subunit-containing GABAA receptors. J Pharmacol Exp Ther 317:369–377
Petursson H (1994) The benzodiazepine withdrawal syndrome. Addiction 89:1455–1459
Pieri L, Schaffner R, Scherschlicht R, Polc P, Sepinwall J, Davidson A, Mohler H, Cumin R, Da Prada M, Burkard WP, Keller HH, Muller RK, Gerold M, Pieri M, Cook L, Haefely W (1981) Pharmacology of midazolam. Arzneimittelforschung 31:2180–2201
Pirker S, Schwarzer C, Wieselthaler A, Sieghart W, Sperk G (2000) GABAA receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 101:815–850
Pugh SL, Boone MS, Emmett-Oglesby MW (1992) Tolerance, cross-tolerance and withdrawal in rats made dependent on diazepam. J Pharmacol Exp Ther 262:751–758
Renger JJ, Dunn SL, Motzel SL, Johnson C, Koblan KS (2004) Sub-chronic administration of zolpidem affects modifications to rat sleep architecture. Brain Res 1010:45–54
Roehrs TA, Randall S, Harris E, Maan R, Roth T (2012) Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol 26:1088–1095
Sanger DJ, Zivkovic B (1987) Investigation of the development of tolerance to the actions of zolpidem and midazolam. Neuropharmacology 26:1513–1518
Sanger DJ, Zivkovic B (1992) Differential development of tolerance to the depressant effects of benzodiazepine and non-benzodiazepine agonists at the omega (BZ) modulatory sites of GABAA receptors. Neuropharmacology 31:693–700
Sanna E, Busonero F, Talani G, Carta M, Massa F, Peis M, Maciocco E, Biggio G (2002) Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABAA receptor subtypes. Eur J Pharmacol 451:103–110
Schmid L, Bottlaender M, Fuseau C, Fournier D, Brouillet E, Mazière M (1995) Zolpidem displays heterogeneity in its binding to the nonhuman primate benzodiazepine receptor in vivo. J Neurochem 65:1880–1886
Sethi PK, Khandelwal DC (2005) Zolpidem at supratherapeutic doses can cause drug abuse, dependence and withdrawal seizure. J Assoc Physicians India 53:139–140
Siegel S (1989) Pharmacological conditioning and drug effects. In: Goudie AJ, Emmett-Oglesby MW (eds) Psychoactive drugs: Tolerance and sensitization. Humana Press, Totowa, pp 115–180
Smith PF, Darlington CL (1994) The behavioural effects of long-term use of benzodiazepine sedative and hypnotic drugs: what can be learned from animal studies? N Z J Psychol 23:48–63
Smith R, Wright BT, Heldt SA (2011) Tolerance and withdrawal effects of zolpidem in mice given chronic zolpidem treatment Society for Neuroscience. Neuroscience Meeting Planner, Washington, DC
Steppuhn KG, Turski L (1993) Diazepam dependence prevented by glutamate antagonists. Proc Natl Acad Sci USA 90:6889–6893
Tietz EI, Huang X, Chen S, Ferencak Iii WF (1999) Temporal and regional regulation of α1, β2 and β3, but not α2, α4, α5, α6, β1 or γ2 GABAA receptor subunit messenger RNAs following one-week oral flurazepam administration. Neuroscience 91:327–341
Trenque T, Bustany P, Lamiable D, Legros S, Choisy H (1994) Pharmacokinetics and brain distribution of zolpidem in the rat after acute and chronic administration. J Pharm Pharmacol 46:611–613
Uusi-Oukari M, Korpi ER (2010) Regulation of GABA(A) receptor subunit expression by pharmacological agents. Pharmacol Rev 62:97–135
van Rijnsoever C, Tauber M, Choulli MK, Keist R, Rudolph U, Mohler H, Fritschy JM, Crestani F (2004) Requirement of α5-GABAA receptors for the development of tolerance to the sedative action of diazepam in mice. J Neurosci 24:6785–6790
Victorri-Vigneau C, Dailly E, Veyrac G, Jolliet P (2007) Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol 64:198–209
Victorri-Vigneau C, Feuillet F, Wainstein L, Grall-Bronnec M, Pivette J, Chaslerie A, Sébille V, Jolliet P (2013) Pharmacoepidemiological characterisation of zolpidem and zopiclone usage. Eur J Clin Pharmacol 1–8
Vinkers CH, Olivier B (2012) Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABAA receptor modulators? Adv Pharmacol Sci. doi:10.1155/2012/416864
Vinkers CH, van Oorschot R, Nielsen EO, Cook JM, Hansen HH, Groenink L, Olivier B, Mirza NR (2012) GABA(A) receptor alpha subunits differentially contribute to diazepam tolerance after chronic treatment. PLoS ONE 7:e43054. doi:10.1371/journal.pone.0043054 PONE-D-11-24285
Vlainic J, Pericic D (2009) Effects of acute and repeated zolpidem treatment on pentylenetetrazole-induced seizure threshold and on locomotor activity: comparison with diazepam. Neuropharmacology 56:1124–1130
Vogel HG, Vogel WH (2002) Drug discovery and evaluation: pharmacological assays. Springer, New York
VonVoigtlander PF, Lewis RA (1991) A rapid screening method for the assessment of benzodiazepine receptor-related physical dependence in mice. Evaluation of benzodiazepine-related agonists and partial agonists. J Pharmacol Methods 26:1–5
Voss J, Sanchez C, Michelsen S, Ebert B (2003) Rotarod studies in the rat of the GABAA receptor agonist gaboxadol: lack of ethanol potentiation and benzodiazepine cross-tolerance. Eur J Pharmacol 482:215–222
Walker MC, Tong X, Brown S, Shorvon SD, Patsalos PN (1998) Comparison of single- and repeated-dose pharmacokinetics of diazepam. Epilepsia 39:283–289
Ward BO, Stephens DN (1998) Sensitisation of withdrawal signs following repeated withdrawal from a benzodiazepine: differences between measures of anxiety and seizure sensitivity. Psychopharmacology 135:342–352
Weerts EM, Griffiths RR (1998) Zolpidem self-injection with concurrent physical dependence under conditions of long-term continuous availability in baboons. Behav Pharmacol 9:285–297
Weerts EM, Ator NA, Grech DM, Griffiths RR (1998) Zolpidem physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. J Pharmacol Exp Ther 285:41–53
Wisden W, Laurie DJ, Monyer H, Seeburg PH (1992) The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J Neurosci 12:1040–1062
Wu Y, Rosenberg HC, Chiu TH, Ramsey-Williams V (1994) Regional changes in [3H]zolpidem binding to brain benzodiazepine receptors in flurazepam tolerant rat: comparison with changes in [3H]flunitrazepam binding. J Pharmacol Exp Ther 268:675–682
Yanagita T, Takahashi S (1973) Dependence liability of several sedative-hypnotic agents evaluated in monkeys. J Pharmacol Exp Ther 185:307–316
Zamanillo D, Sprengel R, Hvalby Ø, Jensen V, Burnashev N, Rozov A, Kaiser KMM, Köster HJ, Borchardt T, Worley P, Lübke J, Frotscher M, Kelly PH, Sommer B, Andersen P, Seeburg PH, Sakmann B (1999) Importance of AMPA receptors for hippocampal synaptic plasticity but not for spatial learning. Science 284:1805–1811
Zhao TJ, Chiu TH, Rosenberg HC (1994) Reduced expression of gamma-aminobutyric acid type A/benzodiazepine receptor gamma 2 and alpha 5 subunit mRNAs in brain regions of flurazepam-treated rats. Mol Pharmacol 45:657–663
Acknowledgments
Support was provided by NIH (MH-086727), NARSAD, and a UTHSC base grant. Some of these results were reported at the meetings of the Society for Neuroscience (Smith et al. 2011). We would like to thank Jordan Marie Ross for her assistance with manuscript preparation and Regina Smith for assistance with data collection.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Online Resource 1
(PDF 302 kb)
Online Resource 2
mRNA expression levels in the amygdala (BLA) and prefrontal cortex (PFC) after sub-chronic treatment (VEH, DZP, or ZOLP). (PDF 301 kb)
Online Resource 3
mRNA expression levels in the cortex, hippocampus, amygdala (BLA) and prefrontal cortex (PFC) after acute (1-day) administration (VEH, DZP, or ZOLP). (PDF 254 kb)
Rights and permissions
About this article
Cite this article
Wright, B.T., Gluszek, C.F. & Heldt, S.A. The effects of repeated zolpidem treatment on tolerance, withdrawal-like symptoms, and GABAA receptor mRNAs profile expression in mice: Comparison with diazepam. Psychopharmacology 231, 2967–2979 (2014). https://doi.org/10.1007/s00213-014-3473-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-014-3473-x